Xenetic Biosciences Inc (NASDAQ:XBIO) Sellers Strengthened By 500% Their Shorts

June 29, 2018 - By Alice Fox

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Corporate Logo

It was showed an increase on Xenetic Biosciences Inc (NASDAQ:XBIO)’s shares shorted with 500%. FINRA announced in June XBIO’s total 600 shares shorted. The 100 previous shares are up with 500%. With Average volume 8,500, XBIO’s former position will take 0 days to restore. Xenetic Biosciences Inc’s shares shorted float is 0.03%.

Ticker’s shares touched $3.9601 during the last trading session after 15.02% change.Currently Xenetic Biosciences, Inc. is downtrending after 48.99% change in last June 29, 2017. XBIO has also 210,799 shares volume. The stock underperformed the S&P 500 by 61.56%.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics.The firm is valued at $34.52 million. The Company’s lead proprietary technology is PolyXen, a platform technology for biologic drug delivery.Currently it has negative earnings. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer.

For more Xenetic Biosciences, Inc. (NASDAQ:XBIO) news posted briefly go to: Benzinga.com, Nasdaq.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “36 Stocks Moving In Monday’s Mid-Day Session” posted on June 25, 2018, “Mid-Morning Market Update: Markets Open Lower; Kroger Earnings Beat Expectations” on June 21, 2018, “26 Stocks Moving In Tuesday’s Pre-Market Session” with a publish date: June 26, 2018, “24 Stocks Moving In Friday’s Pre-Market Session” and the last “40 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: